文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

男男性行为者两剂事件驱动HIV预防方案中增强型与未增强型整合酶链转移抑制剂的药理学比较

Pharmacology of boosted and unboosted integrase strand transfer inhibitors for two-dose event-driven HIV prevention regimens among men.
PubMed 文献 · J Antimicrob Chemother · 2023-01-01

研究在63名18-49岁HIV阴性男男性行为者中比较两剂增强型艾维雷韦与未增强型比克替拉韦方案的药理学。结果显示比克替拉韦血浆浓度在第二剂后96小时仍高于95%蛋白校正有效浓度,而艾维雷韦在第二剂后48小时血浆中已检测不到。两种药物在直肠组织中均于96小时内检测不到,且在阴茎分泌物中未持续检出。

要点

  • 比克替拉韦血浆浓度在第二剂后96小时仍高于95%蛋白校正有效浓度。
  • 艾维雷韦血浆浓度在第二剂后48小时已检测不到,但直肠组织浓度高于比克替拉韦。
  • 两药在阴茎分泌物中均未持续检出,组织分布差异可能影响黏膜与全身抗病毒活性。

核心结论

  • 比克替拉韦血浆浓度在两剂口服HIV预防方案后至少维持4天,而艾维雷韦在黏膜组织中蓄积。
  • 艾维雷韦与比克替拉韦分布不同可能导致黏膜和全身抗病毒活性差异,可为事件驱动HIV预防的给药策略提供参考。

研究设计与样本

  • 从63名18-49岁HIV阴性男男性行为者采集血液、直肠和阴茎分泌物及直肠活检标本。
  • 标本在间隔24小时口服两剂替诺福韦艾拉酚胺和恩曲他滨联合增强型艾维雷韦(考比司他增强)或未增强型比克替拉韦后至96小时内采集。
  • 采用LC-MS测定抗逆转录病毒药物浓度。

主要发现

  • 比克替拉韦血浆平均浓度在给药后96小时仍高于95%蛋白校正有效浓度,为273(95%CI:164-456)ng/mL。
  • 艾维雷韦血浆浓度在第二剂后48小时变得检测不到。
  • 比克替拉韦和艾维雷韦在首剂后2小时内到达直肠组织,艾维雷韦组织浓度[1.07(0.38-13.51)ng/mg]高于比克替拉韦浓度[0.27(0.15-0.70)ng/mg]。
  • 两种整合酶链转移抑制剂在96小时内组织中都变得检测不到。
  • 艾维雷韦和比克替拉韦在阴茎分泌物中未持续检出。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Event-driven HIV prevention strategies are a priority for users who do not require daily pre-exposure prophylaxis (PrEP). Regimens containing integrase strand transfer inhibitors (INSTIs) are under evaluation as alternatives to daily PrEP. To better understand INSTI distribution and inform dosing selection we compared the pharmacology of two-dose boosted elvitegravir and unboosted bictegravir regimens in MSM. MATERIALS AND METHODS: Blood, rectal and penile secretions and rectal biopsies were collected from 63 HIV-negative MSM aged 18-49 years. Specimens were collected up to 96 h after two oral doses of tenofovir alafenamide and emtricitabine with elvitegravir boosted by cobicistat or unboosted bictegravir given 24 h apart. Antiretroviral drugs were measured by LC-MS. RESULTS: Mean bictegravir plasma concentrations remained above the 95% protein-adjusted effective concentration 96 h after dosing [273 (95% CI: 164-456) ng/mL] whereas elvitegravir plasma concentrations became undetectable 48 h after the second dose. Bictegravir and elvitegravir reached rectal tissues within 2 h after the first dose, and elvitegravir tissue concentrations [1.07 (0.38-13.51) ng/mg] were greater than bictegravir concentrations [0.27 (0.15-0.70) ng/mg]. Both INSTIs became undetectable in tissues within 96 h. Elvitegravir and bictegravir were not consistently detected in penile secretions. CONCLUSIONS: Whereas bictegravir plasma concentrations persist at least 4 days after a two-oral-dose HIV prophylaxis regimen, elvitegravir accumulates in mucosal tissues. Differing elvitegravir and bictegravir distribution may result in variable mucosal and systemic antiviral activity and can inform dosing strategies for event-driven HIV prevention.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Haaland RE, Fountain J, Martin A, et al. Pharmacology of boosted and unboosted integrase strand transfer inhibitors for two-dose event-driven HIV prevention regimens among men. J Antimicrob Chemother. 2023. PMID: 36512383. doi:10.1093/jac/dkac419

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。